sb-223245 and Coronary-Disease

sb-223245 has been researched along with Coronary-Disease* in 1 studies

Other Studies

1 other study(ies) available for sb-223245 and Coronary-Disease

Article	Year
Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a restenosis model. Bioorganic & medicinal chemistry letters, 1998, Nov-17, Volume: 8, Issue:22 In the 3-oxo-1,4-benzodiazepine-2-acetic acid series of vitronectin receptor (alpha v beta 3) antagonists, a compound containing an imidazopyridine arginine mimetic was discovered which had sufficient potency and i.v. pharmacokinetics for demonstration of efficacy in a rat restenosis model. Topics: Angioplasty, Balloon, Coronary; Animals; Benzodiazepines; Coronary Disease; Disease Models, Animal; Imidazoles; Pyridines; Rats; Receptors, Vitronectin	1998

Article

Year

Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a restenosis model.

Bioorganic & medicinal chemistry letters, 1998, Nov-17, Volume: 8, Issue:22

In the 3-oxo-1,4-benzodiazepine-2-acetic acid series of vitronectin receptor (alpha v beta 3) antagonists, a compound containing an imidazopyridine arginine mimetic was discovered which had sufficient potency and i.v. pharmacokinetics for demonstration of efficacy in a rat restenosis model.

Topics: Angioplasty, Balloon, Coronary; Animals; Benzodiazepines; Coronary Disease; Disease Models, Animal; Imidazoles; Pyridines; Rats; Receptors, Vitronectin

1998